Allianz Asset Management’s Avidity Biosciences RNAM Stock Holding History

Allianz Asset Management’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-309,887	Closed	-$22.4M	–	2094
2025 Q4	$22.4M	Buy	309,887 +295,387	+2,037%	+$19.1M	0.02%	557
2025 Q3	$632K	Buy	+14,500	New	+$586K	﹤0.01%	1806
2025 Q2	–	Sell	-18,600	Closed	-$549K	–	2244
2025 Q1	$549K	Hold	18,600	–	–	﹤0.01%	1849
2024 Q4	$541K	Hold	18,600	–	–	﹤0.01%	1841
2024 Q3	$854K	Buy	18,600 +8,400	+82%	+$365K	﹤0.01%	1685
2024 Q2	$417K	Buy	+10,200	New	+$293K	﹤0.01%	1891

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return

Allianz Asset Management's RNAM Position: Q1 2026 in Review

Allianz Asset Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 309,887 shares — an estimated $22.4M sold.

Allianz Asset Management first reported a position in RNAM in Q2 2024 and held it in 6 quarters. The position peaked at $22.4M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

Allianz Asset Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
Allianz Asset Management sold 309,887 Avidity Biosciences shares in Q1 2026, an estimated $22.4M.
Allianz Asset Management first reported a position in Avidity Biosciences in Q2 2024 and held it in 6 quarters.
Allianz Asset Management's Avidity Biosciences position peaked at $22.4M in Q4 2025.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.